Ventyx Biosciences (VTYX) to Release Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Ventyx Biosciences Price Performance

Shares of NASDAQ VTYX opened at $13.96 on Wednesday. The firm’s 50-day moving average is $12.40 and its two-hundred day moving average is $7.86. The company has a market capitalization of $1.00 billion, a PE ratio of -9.31 and a beta of 1.25. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $25.00.

Analyst Ratings Changes

Several research analysts have recently weighed in on VTYX shares. Lifesci Capital reiterated a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. UBS Group reissued a “neutral” rating and issued a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Canaccord Genuity Group cut Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $16.00 to $14.00 in a research note on Thursday, January 8th. Finally, HC Wainwright downgraded Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price target for the company. in a research note on Thursday, January 8th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ventyx Biosciences has a consensus rating of “Reduce” and an average price target of $14.00.

Insider Activity

In other news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 18.18% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ventyx Biosciences

A number of institutional investors have recently modified their holdings of VTYX. Virtus Investment Advisers LLC acquired a new position in shares of Ventyx Biosciences during the fourth quarter valued at about $293,000. Wellington Management Group LLP bought a new stake in Ventyx Biosciences during the 4th quarter worth approximately $2,052,000. Squadron Capital Management LLC acquired a new stake in shares of Ventyx Biosciences in the fourth quarter valued at $3,702,000. Tudor Investment Corp ET AL acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $5,270,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $284,000. Institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.